Bluechiip listed on the ASX in June 2011. Since then, we have significantly developed our technology. Today it has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation. Bluechiip: Delivering confidence in every sample.
Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way.
Bluechiip’s advanced sample management solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip’s solution delivers confidence in every sample.
Corporate Presentation
Download the latest corporate update - April 2023
Research notes
MST Access Research Report - May 2023
MST Access Research Report - April 2023
MST Access Research Report - May 2023
Reports and Notices
Download Bluechiip’s most recent Annual and Quarterly reports from the links below:
Notice of 2022 Annual General Meeting - October 2022
Preliminary Final Report - August 2022
Quarterly Activities/Appendix 4C Cash Flow Report - July 2022
Quarterly Activities/Appendix 4C Cash Flow Report - Mar 2022
Appendix 4D & Half Year Financial Report - Dec 2021
Quarterly Activities/Appendix 4C Cash Flow Report - Dec 2021
Quarterly Activities/Appendix 4C Cash Flow Report - Sep 2021